BMS Partners with Anthropic for AI Drug Discovery

Bristol Myers Squibb (BMS) has entered a strategic partnership with AI safety and research company Anthropic ^[1]. The collaboration aims to integrate Anthropic’s Claude AI model across BMS's global operations, focusing on drug research and development ^[2]. This move represents a major expansion of the pharmaceutical company's commitment to artificial intelligence ^[1].

The partnership extends beyond basic research into manufacturing and regulatory systems ^[3]. BMS plans to use the Claude model to streamline quality control and accelerate the delivery of new treatments to patients ^[2][3]. By adopting enterprise-wide AI, the company seeks to enhance data analysis and operational efficiency ^[1].

Anthropic's Claude will assist with complex documentation and data processing tasks required for drug approval ^[2]. Industry experts suggest this deal signals a broader trend of big pharma adopting advanced AI for end-to-end pharmaceutical development ^[3].